Dare Bioscience, Inc. (DARE): EBITDA

Operating income plus depreciation and amortization for the same annual period and currency, computed by TickerFacts from the filed figures. Not the company's adjusted EBITDA; a year without both inputs is left out.

-$11.92M

Year ended 2025-12-31

2016-12-31 EBITDA (USD) 2025-12-31

Period ended	EBITDA	Change YoY	Source filing
2025-12-31	-$11.92M	n/m	2026-03-26, From 2025-01-01
2024-12-31	-$23.41M	n/a	2026-03-26, From 2024-01-01
No annual figure between 2016-12-31 and 2024-12-31.
2016-12-31	-$369.6K	n/a	2018-03-28, From 2016-01-01

EBITDA at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	EBITDA	Change YoY
Dare Bioscience, Inc. (DARE)	2025-12-31	-$11.92M	n/m
60 Degrees Pharmaceuticals, Inc. (SXTP)	2025-12-31	-$7.72M	n/m
Shattuck Labs, Inc. (STTK)	2025-12-31	-$47.81M	n/m
China SXT Pharmaceuticals, Inc. (SXTC)	2026-03-31	-$7.05M	n/m
Rafael Holdings, Inc. (RFL)	2025-07-31	-$28.87M	n/m
Neuphoria Therapeutics Inc. (NEUP)	2026-06-30	-$15.79M	n/m
Longeveron Inc. (LGVN)	2025-12-31	-$22.49M	n/m
Rallybio Corp (RLYB)	2025-12-31	-$32.97M	n/m
Vistagen Therapeutics, Inc. (VTGN)	2026-03-31	-$71.93M	n/m

Compare DARE, SXTP, STTK, SXTC side by side · Screen every company in Pharmaceutical Preparations ↗